France's LEEM hosts week-long public debates

21 October 2007

France's drug industry association (LEEM) has announced the timetable for its week-long series of debates and other public events for the second annual "Medications, let's talk about them" week, with the theme this year of "Has Innovation broken down?" (Marketletter October 15). A number of these are hosted in Paris from October 15-21.

On the Monday, at the Gare St Lazare, the Association France Alzheimer and the LEEM are co-hosting a debate on the topic: Alzheimer's disease, where are we at? The debate is open to members of patient groups and the general public and is organized to coincide with an exhibition about the condition.

On the Tuesday, a gathering of parliamentarians under the chairmanship of former Prime Minister and current Senator Jean-Pierre Raffarin (Union for a Popular Movement [UMP], Vienne) at the Maison des Arts et Metiers will discuss three topics: have there been genuine therapeutic advances in the past 10 years; can treatment innovation be a generator of economic growth; and what is to be done to ensure that France remains a leading center of pharmaceutical innovation? On the same day, a student group will host the first of two debates on health care responsibility at the Cafe Basile (the second being held on the Thursday).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight